Canadian Cancer Trials Group Bulletins


2011 ASCO Annual Report on Progress Against Cancer

Two Canadian Cancer Trials Group-led trials (MAP.3 and MA.20) and one trial that included Canadian Cancer Trials Group participation (OV.19) were included as "Major Advances" in ASCO's 2011 Annual Report on Progress Against Cancer (

Canadian Cancer Trials Group MAP.3 - A Phase III Randomized Study of Exemestane versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
The results of MAP.3 showed that exemestane (Aromasin®), a member of a family of drugs called aromatase inhibitors, reduced the risk of developing breast cancer compared with placebo in high-risk, postmenopausal women (see pages 3 and 9).

Canadian Cancer Trials Group MA.20 - A Phase III Study of Regional Radiation Therapy in Early Breast Cancer
The results of this trial showed that adding radiation to the regional lymph nodes reduces the risk of cancer recurrences both near the tumour and in other parts of the body in women with early-stage breast cancer who have one to three cancer-positive lymph nodes (or high-risk node-negative breast cancer) (see pages 6 and 9).

Canadian Cancer Trials Group OV.19 (ICON7) - A Randomized, Two-Arm, Multi-Centre Gynecologic Cancer Intergroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin And Paclitaxel) in Patients with Epithelial Ovarian Cancer
Interim data from this trial suggested that adding bevacizumab to standard carboplatin and paclitaxel chemotherapy for treatment of newly diagnosed ovarian cancer may offer a survival benefit over treatment with chemotherapy alone, particularly for patients with more aggressive
disease (see pages 4-9 and 19).